220 related articles for article (PubMed ID: 9179219)
1. Value of 18fluoro-deoxyglucose positron emission tomography in the staging of recurrent breast carcinoma.
Bender H; Kirst J; Palmedo H; Schomburg A; Wagner U; Ruhlmann J; Biersack HJ
Anticancer Res; 1997; 17(3B):1687-92. PubMed ID: 9179219
[TBL] [Abstract][Full Text] [Related]
2. The role of (18)F-FDG PET/CT in initial staging of patients with locally advanced breast carcinoma with an emphasis on M staging.
Mittal BR; Manohar K; Kashyap R; Bhattacharya A; Singh B; Singh G
Hell J Nucl Med; 2011; 14(2):135-9. PubMed ID: 21761015
[TBL] [Abstract][Full Text] [Related]
3. Value of whole body 18F-fluoro-2-deoxyglucose positron emission tomography in the evaluation of recurrent cervical cancer.
Sun SS; Chen TC; Yen RF; Shen YY; Changlai SP; Kao A
Anticancer Res; 2001; 21(4B):2957-61. PubMed ID: 11712793
[TBL] [Abstract][Full Text] [Related]
4. Axillary lymph node metastases: screening with [F-18]2-deoxy-2-fluoro-D-glucose (FDG) PET.
Adler LP; Faulhaber PF; Schnur KC; Al-Kasi NL; Shenk RR
Radiology; 1997 May; 203(2):323-7. PubMed ID: 9114082
[TBL] [Abstract][Full Text] [Related]
5. Decision logic for retreatment of asymptomatic lung cancer recurrence based on positron emission tomography findings.
Frank A; Lefkowitz D; Jaeger S; Gobar L; Sunderland J; Gupta N; Scott W; Mailliard J; Lynch H; Bishop J
Int J Radiat Oncol Biol Phys; 1995 Jul; 32(5):1495-512. PubMed ID: 7635795
[TBL] [Abstract][Full Text] [Related]
6. FDG PET and immunoscintigraphy with 99mTc-labeled antibody fragments for detection of the recurrence of colorectal carcinoma.
Willkomm P; Bender H; Bangard M; Decker P; Grünwald F; Biersack HJ
J Nucl Med; 2000 Oct; 41(10):1657-63. PubMed ID: 11037995
[TBL] [Abstract][Full Text] [Related]
7. Value of combined FDG PET and MR imaging in the evaluation of suspected recurrent local-regional breast cancer: preliminary experience.
Hathaway PB; Mankoff DA; Maravilla KR; Austin-Seymour MM; Ellis GK; Gralow JR; Cortese AA; Hayes CE; Moe RE
Radiology; 1999 Mar; 210(3):807-14. PubMed ID: 10207485
[TBL] [Abstract][Full Text] [Related]
8. Detection of locoregional and distant recurrences in breast cancer patients by using FDG PET.
Eubank WB; Mankoff DA; Vesselle HJ; Eary JF; Schubert EK; Dunnwald LK; Lindsley SK; Gralow JR; Austin-Seymour MM; Ellis GK; Livingston RB
Radiographics; 2002; 22(1):5-17. PubMed ID: 11796893
[TBL] [Abstract][Full Text] [Related]
9. Positron emission tomography/computed tomography with 18fluoro-deoxyglucose in the detection of local recurrence and distant metastases of pediatric sarcoma.
Arush MW; Israel O; Postovsky S; Militianu D; Meller I; Zaidman I; Sapir AE; Bar-Shalom R
Pediatr Blood Cancer; 2007 Dec; 49(7):901-5. PubMed ID: 17252575
[TBL] [Abstract][Full Text] [Related]
10. Value of FDG PET in papillary thyroid carcinoma with negative 131I whole-body scan.
Chung JK; So Y; Lee JS; Choi CW; Lim SM; Lee DS; Hong SW; Youn YK; Lee MC; Cho BY
J Nucl Med; 1999 Jun; 40(6):986-92. PubMed ID: 10452315
[TBL] [Abstract][Full Text] [Related]
11. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma.
Moon DH; Maddahi J; Silverman DH; Glaspy JA; Phelps ME; Hoh CK
J Nucl Med; 1998 Mar; 39(3):431-5. PubMed ID: 9529287
[TBL] [Abstract][Full Text] [Related]
12. The value of positron emission tomography in the follow-up for breast cancer.
Siggelkow W; Zimny M; Faridi A; Petzold K; Buell U; Rath W
Anticancer Res; 2003; 23(2C):1859-67. PubMed ID: 12820470
[TBL] [Abstract][Full Text] [Related]
13. Qualitative [18F]FDG positron emission tomography in primary breast cancer: clinical relevance and practicability.
Scheidhauer K; Scharl A; Pietrzyk U; Wagner R; Göhring UJ; Schomäcker K; Schicha H
Eur J Nucl Med; 1996 Jun; 23(6):618-23. PubMed ID: 8662094
[TBL] [Abstract][Full Text] [Related]
14. Is combined 18F-fluorodeoxyglucose-positron emission tomography/computed tomography superior to positron emission tomography or computed tomography alone for diagnosis, staging and restaging of pancreatic lesions?
Casneuf V; Delrue L; Kelles A; Van Damme N; Van Huysse J; Berrevoet F; De Vos M; Duyck P; Peeters M
Acta Gastroenterol Belg; 2007; 70(4):331-8. PubMed ID: 18330088
[TBL] [Abstract][Full Text] [Related]
15. Prospective evaluation of fluorine-18 fluorodeoxyclucose positron emission tomography in breast cancer for staging of the axilla related to surgery and immunocytochemistry.
Utech CI; Young CS; Winter PF
Eur J Nucl Med; 1996 Dec; 23(12):1588-93. PubMed ID: 8929312
[TBL] [Abstract][Full Text] [Related]
16. Role of 2-[18F] fluoro-2-deoxy-D-glucose-positron emission tomography/computed tomography in the post-therapy surveillance of breast cancer.
Chang HT; Hu C; Chiu YL; Peng NJ; Liu RS
PLoS One; 2014; 9(12):e115127. PubMed ID: 25517451
[TBL] [Abstract][Full Text] [Related]
17. Mediastinal staging of non-small-cell lung cancer with positron emission tomography.
Chin R; Ward R; Keyes JW; Choplin RH; Reed JC; Wallenhaupt S; Hudspeth AS; Haponik EF
Am J Respir Crit Care Med; 1995 Dec; 152(6 Pt 1):2090-6. PubMed ID: 8520780
[TBL] [Abstract][Full Text] [Related]
18. Role of positron emission tomography in staging esophageal cancer.
Luketich JD; Schauer PR; Meltzer CC; Landreneau RJ; Urso GK; Townsend DW; Ferson PF; Keenan RJ; Belani CP
Ann Thorac Surg; 1997 Sep; 64(3):765-9. PubMed ID: 9307471
[TBL] [Abstract][Full Text] [Related]
19. Staging non-small cell lung cancer with whole-body PET.
Marom EM; McAdams HP; Erasmus JJ; Goodman PC; Culhane DK; Coleman RE; Herndon JE; Patz EF
Radiology; 1999 Sep; 212(3):803-9. PubMed ID: 10478250
[TBL] [Abstract][Full Text] [Related]
20. Lymphoma: role of whole-body 2-deoxy-2-[F-18]fluoro-D-glucose (FDG) PET in nodal staging.
Moog F; Bangerter M; Diederichs CG; Guhlmann A; Kotzerke J; Merkle E; Kolokythas O; Herrmann F; Reske SN
Radiology; 1997 Jun; 203(3):795-800. PubMed ID: 9169707
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
